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A B S T R A C T
Epigenetics refers to the study of heritable changes in gene expression that occur without a change in DNA sequence.
In the last decade, it has been shown that epigenetic mechanisms provide an »extra« layer of transcriptional control that
regulates genes expression. Three distinct mechanisms appear intricately related in initiating and sustaining epigenetic
modifications: RNA-associated silencing, DNA methylation and histone modification. These mechanisms are critical
components in the normal development and cell growth. DNA methylation is involved in transcriptional silencing of
genes, regulation of expression of imprinted genes, a number of tumour suppressor genes in cancer and silencing of genes
located on the inactive X chromosome. In this review, we are focused on the basic principles of DNA methylation as the
main epigenetic mechanism for normal embryonic development and epigenetic alterations that contribute to carcino-
genesis.
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Introduction
Genomic DNA represents the base of cellular genetic
information contained in a sequence of four nitrogen
bases: adenine, guanine, thymine and cytosine1. The se-
quence of these four bases determines the primary struc-
ture of DNA, but it still does not mean that the existing
sequence is really going to be transcribed and translated,
i.e. the sequence would undergo expression2. Despite the
fact that every single cell of our body contains the identi-
cal set of chromosomes, there are big differences among
these cells both in their shape and in their functions. So,
the cells of a multicellular organism are genetically ho-
mogeneous, but structurally and functionally they are
heterogeneous due to differential gene expression3. It im-
plies that these cells activate only those genes which are
indispensable for their functioning and survival, while
the rest of genes remain inactive4. Such a pattern of dif-
ferential gene activation has been established very early
during the period of embryonic development, and further
on it is stably inherited from one cell generation to the
next5. It is clear therefore, that there must be an addi-
tional level of control over the observed genetic activity,
totally independent from the primary DNA structure6.
Such variability of gene expression which is not the con-
sequence of a change in DNA sequence is the topic of in-
terest for epigenetics, the term used for the first time in
the fifties by Conrad Waddington7,8. Epigenetic inheri-
tance may be described as the transmission of informa-
tion from a cell or multicellular organism to its descen-
dants without that information being encoded in the
nucleotide sequence of the gene. All of our cells contain
the same number of genes; however, in a given tissue and
at a given state, owing to an epigenetic code, only some of
these genes are expressed, giving rise to the phenotype.
Three systems, including DNA methylation, histone mo-
dification and RNA-mediated action, are considered to-
day of having roles in regulation of gene expresion9. Up-
setting any single factor of this interactive system could
bring about inadequate gene expression and consequent-
ly present epigenetic diseases10.
Here we are going to concentrate primarily on DNA
methylation as one among the essential mechanisms for
regulation of gene expression in mammals, and the other
stakeholders in this story will be mentioned only for sake
of better understanding of the mechanisms of action of
methylation on gene expression.
665
Received for publication March 28, 2006
The Process of DNA Methylation
Methylation process is one among the key mecha-
nisms for modification of DNA molecule, and hence the
epigenetic control of gene expression in vertebrates11.
Such a regulatory mechanism allows a cell to stop tran-
scription, ensures inactivity of the majority of genes of
one X chromosome of the female organism, and enables
the process of genomic imprinting, as well as protection
of the endogenous genome from eventual intrusion of a
parasitic genome12,13. The very mechanism of methyla-
tion refers to the binding of a methyl group to the 5th
carbon atom of the cytosine ring, and is carried out with
the help of the enzyme DNA methyltransferase (Dnmt).
The result is the formation of a new base, 5-methyl-
cytosine (5mC)14,15. Addition of the methyl group is a pro-
cess which takes place immediately after replication, and
is completed within 1 minute after completion of repli-
cation16,17. The result of such modification changes the
affinity for particular transcription factors towards DNA
molecule which prevents the formation of the trans-
criptional initiation complex, or elongation of those al-
ready initiated, that is gene silencing18.
DNA methylation typically occurs in a CpG dinu-
cleotide regions of DNA19. Assuming random distribu-
tion of nucleotides the probability of a cytosine and gua-
nine lying next to each other is very high. However, there
are actually very few CpG sites in eukaryotic genomes20.
This is due to the action of DNA methyltransferase,
which recognizes these CpG sites and methylates the cy-
tosine, turning it into 5-methylcytosine. Following spon-
taneous deamination, the 5-methylcytosine converts into
thymine. If this has no effect (as in most cases), the error
is not recognized by the repair machinery, thus resulting
in the loss of the CpG site. CpG sites thus tend to be elim-
inated from the genomes of eukaryotes21.
In mammals there are so far discovered 5 members of
the family of DNA (cytosin-5) methyltransferases, en-
zymes involved in the methylation of CpG sequences:
Dnmt 1, Dnmt 2, Dnmt3a, Dnmt 3b and Dnmt3L22,23.
Dnmt1 is the proposed maintenance methyltransferase
that is responsible for copying of the already established
methylation pattern by recognizing the hemimethylated
sites in DNA helix, and it is present always in replication
forks of the cells undergoing division24,25. Inactivation of
this enzyme in mice brings about the global loss of
methylation and abnormal biallelic expression of im-
printed genes26,27. In contrast to Dnmt1, the biological
activity of Dnmt2 does not demonstrate affinity towards
CpG sequences, and knock-out mice for this gene do not
show recognizable abnormalities28. It is assumed that
this enzyme plays some role in DNA methylation, but it
appears not to have any DNA methyltransferase acti-
vity29. Dnmt3a and Dnmt3b participate in processes of de
novo methylation that sets up DNAmethylation patterns
early in development.. Kaneda et collaborators reported
the disruption of Dnmt3a and Dnmt3b in germ cells,
with their preservation in somatic cells, by conditional
knockout technology. Offspring from Dnmt3a conditio-
nal mutant females died in utero and lacked methylation
and allele-specific expression at all maternally imprinted
loci examined. Dnmt3a conditional mutant males sho-
wed impaired spermatogenesis and lacked methylation
at 2 of 3 paternally imprinted loci examined in spermato-
gonia. By contrast, Dnmt3b conditional mutants and
their offspring showed no apparent phenotype. The phe-
notype of Dnmt3a conditional mutants is indistinguish-
able from that of Dnmt3L knockout mice, except for the
discrepancy in methylation at 1 locus (IG-DMR). The
conclusion was drawn that both Dnmt3a and Dnmt3L are
required for methylation of most imprinted loci in germ
cells, but other factors are probably involved30.
Beside these randomly distributed CpG sites there
are regions of the genome which contain extremely high
concentration of CpG sites. The concentration of these
dinucleotides is more than ten times higher than in the
rest of the genome31. These regions, known as CpG is-
lands, are found at the promoters of 50–60% of all human
genes32,33. Surprisingly, these CpG sites are unme-
thylated, and therefore any spontaneous deaminations of
cytosine to uracil are recognized by the repair machinery
and the CpG site is restored.
The question is being raised on how does the DNA
methylation influence gene expression, i.e. how is the
gene repression acquired by the mechanism of DNA
methylation? It is considered that the repression pro-
ceeds in two ways: (1) directly – the methylation of CpG
sequences changes the recognition site for a particular
transcriptional factor, so that it does not recognise it any
more and does not bind to it, and (2) indirectly – by bind-
ing of specific proteins which have affinity for methyl-
ated CpG sequences34. These are the proteins which bind
to methylated CpG groups (methyl-CpG binding pro-
teins, MeCPs), via a domain responsible for binding to
CpG sequences (methyl-CpG binding domain, MBD), and
are consequently called MBD1, MBD2, MBD3, MeCP1
and MeCP235,36. MeCP2 is a transcription factor that rec-
ognizes and binds to a symmetrically methylated CpG
dinucleotide37. It is also a component of the histone
deacetylase complex38. MBD1 is included in histone de-
acetylation, too, while MBD2 is a part of MeCP1 protein
complex which mediates the methylation-dependent re-
pression of transcription39,40. The indirect repression of
transcription which includes the mentioned proteins is
undoubtedly connected with the degree of histone ace-
tylation41. Every histone contains a domain which is re-
sponsible for mutual histone interactions and winding of
DNA around them, and an aminoterminal end which
protrudes out of the nucleosome, by which histones com-
municate with other regulatory proteins42. The amino-
terminal domain is rich in lysine, which are the most fre-
quent targets for acetylation, which in turn markedly
decrease the affinity of histone H4 for DNA43. It is being
considered that the histone acetylation is the molecular
mechanism by which DNA becomes generally available
for trans-regulatory factors, and at the same time retain-
ing further the nucleosomal architecture44. DNA methy-
lation together with such chromatin organisation con-
tributes to repression of transcription by stimulating
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binding of MeCP2 and the recruiting complex of histone
deacetylation45,46. This suggests that specific behaviour
of chromatin containing methylated DNA region forms
molecular key-lock which might permanently silence
down the transcriptional process47. Capacity of DNA
methylation to increase the repression of transcription
by reorganizing chromatin, largely contributes to ge-
nome division into hetero- and euchromatin in differenti-
ated cells48. Covalent modifications of nucleosomal his-
tones, like acetylation, methylation, phosphorylation and
ubiquitinalization, comprise unique and sufficient gene
configuration, promoting the idea which subordinates
the genetic code to superior epigenetic regulatory system
known as the »histone code«49,50. »Histone code« is repre-
sented by histone modifications like methylation of ly-
sine 9 in H3 histone (H3mK9) and absence of acetylation
of histones H3 and H4 in heterochromatin, and the other
way aroundmethylation of lysine 4 in histone H3 (H3mK4)
and acetylation of histones H3 and H4 in euchroma-
tin51,52.
DNA Methylation and Embryonic
Development
Embryonic development in mammals demonstrates
the bimodal reprogramming of DNA methylation, which
takes place in primordial germ cells (PGC), where the
loss of methylation is connected with the creation of new
methylation pattern specific for male or female gamete.
After fertilization and during the preimplantation period
the loss of methylation enables establishment of the
totipotency of zygote53. Upon entrance into germinal
ridge, particularly methylated PGC, undergo rapid deme-
thylation followed by de novo methylation, and so the
mature gametes display a high degree of methylation54,55.
Surprisingly, recent data showed the ability of an en-
vironmental factor (for example, endocrine disruptor) to
reprogram the germ line and to promote even a trans-
generational disease. Namely, transient exposure of a
gestating female rat during the period of gonadal sex de-
termination to the endocrine disruptors induced an adult
phenotype in the F1 generation of decreased sperma-
togenic capacity and increased incidence of male infertil-
ity. These effects are transferred through the male germ
line to nearly all males of subsequent generations up to
F4. The effects on reproduction correlate with altered
DNA methylation patterns in the germ line56.
Not only environmental factors, but even nutritional
intervention is connected to altered DNA methylation
patterns with transgenerational effects57. The finding is
remarkable because it suggests that a pregnant mother's
diet can affect her health in such a way that not only her
children but her grandchildren and possibly great-grand-
children inherit the same health problems.
In another study in northern Sweden grandparent's
prepubertal access to food was correlated with diabetes
and heart disease. If food was not readily available dur-
ing the father's slow growth period, then cardiovascular
disease mortality of the proband was low. Diabetes mor-
tality increased if the paternal grandfather was exposed
to a surfeit of food during his slow growth period58.
Nevertheless, there are still strong evidences that af-
ter fertilization the loss in DNA methylation takes place
in both pronuclei. This methylation decline is stronger in
paternal DNA which becomes demethylated several
hours after fertilization, so it is considered to be the con-
sequence of active demethylation, despite the fact that
enzymes responsible for this active demethylation are
not identified up to now59. Parallel with this process, the
exchange of protamines with histones is taking place in
paternal pronucleus60. Maternal pronucleus also under-
goes demethylation, but it is more gradual and dimin-
ishes after each replication cycle for the lack of Dnmt1
responsible for the maintenance of methylation pattern61.
Such a replication-dependent decline in methylation is
called passive demethylation62. The second wave of me-
thylation reprogramming takes place during the period
between fertilization and appearance of blastocyst63.
The crucial role of proper DNA methylation pattern
changes during development was showed by our work
with 5-azacytidine, a demethylating agent which was ad-
ministered to pregnant rats in different stages of gesta-
tion. After application on day 12 and day 13 of pregnancy
survival of foetuses was drastically reduced and limb
malformations were present64. Moreover, the placentas
were influenced as well when the methylation pattern
was disturbed, in a way that not only the placental struc-
ture, but even the expression of different glycoprotein’s
was disturbed (own unpublished results).
Imprinted Genes and Human
Disorders
Despite such a global loss in methylation, certain
genomic sequences are excepted from this process in the
preimplantation embryo. It is primarily about the im-
printed genes whose expression depends on the fact
whether they are inherited from mother or from father
e.g. they are monoallelically expressed in contrast to
most genes where two alleles contribute equally to the
production of gene product65. The first experiments
which have indicated the existence of imprinted genes in
the mammalian genome were carried out by McGrath
and Solter, by establishing the method for transplanta-
tion of nuclei into enucleated mammalian oocytes66.
These experiments have shown that the prerequisite for
the normal embryonic development of mammals is the
genetic information contained in gametes of both par-
ents. Gynogenetic embryos obtained by combining two
female pronuclei were small and morphologically nor-
mal, but without extraembryonic membranes and were
spontaneously aborted67. On the other hand, androge-
netic embryos obtained by combining two male pronuclei
developed normal extraembryonic membranes, but the
embryonic part was reduced, a phenomenon almost iden-
tical to that occurring occasionally in abnormal human
pregnancy, when instead of normal embryo one finds for-
mation called mola hydatidosa68. Mola is aggregate of
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extraembryonic membranes without presence of foetal
tissue, and its chromosomal composition is mostly that of
the father69,70.
The mentioned data speak in favour that the expres-
sion of each of the parental genomes is different, and it is
crucial that they mutually complement each other if we
want to have the normal development71. The question is
raised whether mammalian zygotes for their normal de-
velopment require the presence of total paternal and ma-
ternal genome, or only of particular chromosomes, or
even some critical genes. Experiments with mouse em-
bryos which contained rearranged parts of some chromo-
somes, showed that particular genes or groups of genes
are active when inherited from one parent, and inactive
when inherited from from parent of opposite sex72.
The first discovered imprinted genes were insulin-like
growth factor 2 receptor (Igf2r) gene73 discovered in the
year 1991 and a few months later Igf2. At the time
DeChiara and collaborators have observed that targeted
mutation in this gene results in dwarfed growth in het-
erozygotes, but only in the case when the paternal gene
is involved (and not the maternal gene). The reduced
growth in the newborns was identical in heterozygotes
with mutant paternal gene and in recessive homozy-
gotes, indicating that only father influences the activity
of Igf2 gene74. Discoveries of new imprinted genes fol-
lowed, particularly after establishing the method for re-
striction landmark genome scanning (RLGS) which was
based on the fact that the „imprinting« is connected with
methylation of CpG dinucleotides identifiable using this
method75.
The imprinted genes display certain, for themselves
specific rules like the fact that so far identified genes are
not randomly dispersed in the genome as singular genes,
but display tendency for grouping76. One among the larg-
est groups is located on the distal end of the mouse chro-
mosome 7 as well as on the proximal end of the human
chromosome 1177. In the majority of such groups one
finds interwoven maternally and paternally imprinted
genes78. To date over 70 human imprinted genes have
been identified of a total of 100–200 expected in the
whole genome. These imprinted domains are regulated
co-ordinately, via long-range mechanisms such as anit-
sense RNA interference and methylation-sensitive boun-
dary elements. The largest group of imprinted genes is
located on the X chromosome79,80. It is known that in the
female mammals, the dose compensation for genes on X
chromosome is acquired by inactivation of one X chromo-
some in all somatic cells81. Although this inactivation is
random, it appears that in the extraembryonic tissues
the paternal X is turned off more frequently, with the
only exception of Xist gene, which represent the inactiva-
tion centre and is the only active gene on the inactive
chromosome, and vice versa the only inactive one on the
active chromosome82,83. In any case inactivation of X
chromosome as well as genomic imprinting of autosomal
genes generates functional hemizygotes84.
It seems that reason for grouping of imprinted genes
in the genome is that the control of their expression is ex-
ecuted from the single cis-regulatory sites called imprint-
ing control regions (ICRs) or differentially methylated
domains (DMDs). Their distinctive characteristic is that
they are always methylated on one of the two parental
alleles85,86. The deletion of these sites eliminates imprint-
ing and consequently both alleles are expressed87. Partic-
ularly interesting and well studied is the ICR between
H19 and Igf2 genes on the human chromosome 11,
methylation of which may be responsible either for acti-
vation or inactivation of the above genes depending on
the choice of whether it is methylated on the maternal or
paternal chromosome88. The behaviour of these two
genes illustrates how differently they may react depend-
ing on the state of methylation of the control region
which is located between them89. This region is methyl-
ated on the paternal chromosome and consequently H19
is inactive, while Igf2 is expressed and active90. On the
contrary, on the maternal chromosome the same region
is not methylated, so now H19 becomes active, and Igf2
inactive91. In this case the control region behaves as an
insulator. The insulators are regulatory elements which
prevent the activation or inactivation of genes, and can
be found between promoters and enhancers, or even on
the border between transcriptionally active euchroma-
tine and inactive heterochromatine92,93. When the ICR is
unmethylated, it is the binding site for CTCF which be-
longs to the group of transcriptional regulatory proteins
with the Zink finger motif, by which it prevents activa-
tion action of enhancer upon the promoter of Igf2 gene94.
Here we see an unusual way of regulation of gene expres-
sion, where methylation indirectly activates the gene by
blocking the insulator95. Regulation of H19 expression in
much more common because its methylation creates in-
active, i.e. imprinted site, so the methylation directly af-
fects the activity of the promoter96.
The second significant characteristic of imprinted ge-
nes is their temporarily uncoordinated (asynchronous)
replication in relation to the active alleles on the homolo-
gous chromosome97. It has been observed that Igf2 gene
and gene for its receptor (Igf2r), as well as H19 and
SNRPN are replicating earlier in S-phase of the cell cycle
if they are of paternal origin98. Even though the time of
replication within the cell cycle very frequently corre-
lates with the degree of gene expression, so that active
genes are mostly replicated at the beginning of the S-
phase, this is not the general rule, inasmuch as H19 and
Igf2r normally transcribed from maternal chromosome
are replicated earlier on paternal chromosome99. In real-
ity, it appears that, within the so far studied imprinted
genes, and irrespective of the degree of gene expression,
the paternal allele always replicates first, which has been
demonstrated by the method of fluorescent in situ hy-
bridization (FISH) suitable for visualization of particular
genes during S-phase of the cell cycle100,101.
It is surprising that almost half of the so far discov-
ered imprinted genes does not code for proteins but for
untraslated RNA. So the RNA molecule of the H19 gene
expressed only from mother is indispensable during em-
bryonic development and required for imprinting of the
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other two genes which are transcribed from paternal
chromosome102. Imamura and collaborators have proved
that RNA which is not translated may induce demethy-
lation of the tissue specific differentially methylated do-
main, which might serve as a potential new tool in
epigenetic manipulation of mammalian cells103.
Importance of methylation and consequently of ge-
nomic imprinting is unquestionable for normal function-
ing of an organism, which is documented by numerous
diseases associated with inadequate methylation or with
mutation of enzymes responsible for methylation and by
them mediated repression of transcription104. Classical
examples associated with the phenomenon of genomic
imprinting are two rare diseases which are a mirror im-
age of each other105. Both include a disturbance in growth
and behaviour, and are called Angelman and Prader-Willi
syndromes106. They are both caused by the identical chro-
mosomal deletion of chromosome15107. When the deletion
is inherited from the mother it results in the phenotype
of Angelman syndrome, while the same deletion inheri-
ted from father gives rise to Prader-Willi syndrome108,109.
The loss of genomic imprinting of the chromosome
11p15.5 presents the Beckwith-Wiedmann syndrome
which is characterized by embryonic tumours, excessive
growth of abdominal organs, macroglossia and ompha-
locoela110. Mutation of the gene MeCP2 and enzyme in-
cluded in methylation-mediated repression of transcrip-
tion, brings about the neurological disease known as Rett
syndrome which affects one out of 10.000 newborn girls,
though up to now the effect of sex on development of this
disease has not been discovered111. It is considered that
the mutation of this enzyme brings about disturbance in
differentiation of primary neurones112. Consequently mi-
crocephalia, ataxia, and tonic clonic seizures are develo-
ped113.
Epigenetic reprogramming is considered today as one
among the most significant barriers to cloning, because
when a differentiated somatic cell nucleus is put into
oocyte, its genome-wide epigenetic pattern must be re-
programmed in order to restore totipotency. The difficul-
ties associated with reprogramming in chromatin, his-
tones, and methylation patterns along the entire length
of the DNA sequence may explain why so many cloned
embryos have so many developmental failures. And even
after assisted reproduction there is elevated incidence of
diseases associated with imprinting114,115. The reason for
this may be because these methods, and particularly in
vitro fertilisation (IVF) and intracytoplasmyc sperm in-
jection (ICSI), include isolation, handling and cultivation
of both gametes and embryos in early embryonic phase,
when the genome methylation pattern changes dynami-
cally, so the above mentioned cells are found themselves
in a particularly vulnerable period during which this pat-
tern might be disturbed116,117. The number of the up to
now reported cases connected with these issues is too
small to enable making any generalized conclusions, but
in any case requests further scientific engagement in or-
der to eventually eliminate the problems connected with
genomic imprinting and the methods of assisted repro-
duction118.
DNA Methylation and Carcinogenesis
During the past several years the interest of many sci-
entists who are engaged in epigenetics has broadened
into the field of carcinogenesis, because the status of
DNA methylation changes during life, hence affecting
the expression of genes associated with development of
cancer119,120. Epigenetic silencing as the consequence of
aberrant methylation of promoter regions, and CpG is-
lands results in the loss of function of tumour suppressor
genes121,122. Tumour cells frequently show increased ac-
tivity of DNA methyltransferases, which are responsible
for hypermethylation of promoters of these genes123,124.
But there are no genetic proofs that would indicate the
ectopic de novo methylation in cancer, neither for DNA
methyltransferase genes mutations. Instead it is hypoth-
esized that the cause is somewhere in the transcriptional
machinery or in a signal transduction pathway genes125.
So Butcher et al. consider that inactivation or disruption
of these insulators may facilitate an epigenetic »hit«, in
this case DNA methylation, leading to down regulation
of tumor-supressor gene (e.g. BRCA1) contributing to
tumorigenesis126. It follows from the above mentioned,
that the epigenetic changes, i.e. the silencing of tu-
mor-supressor gene promoters by methylation would
trigger carcinogenesis. However, it is known that DNA
methyltransferase gene mutation does not change the
frequency of tumour appearance127. In some cell lines of
colorectal carcinoma one mutant allele of p16 gene has
been found, which is therefore non-functional, but ex-
pressed, while its homologue was hypermethylated and
totally silenced128. As the methylation can be detected
very precisely with contemporary techniques, and the ex-
tent of methylation established in any sort of cells, the
connection of methylation with appearance of cancer
gives hope for discovery of new potential ways for pre-
vention and treatment of these diseases129.
Recent evidence indicates that epigenetic changes
might 'addict' cancer cells to altered signal-transduction
pathways during the early stages of tumour develop-
ment. Dependence on these pathways for cell prolifera-
tion or survival allows them to acquire genetic mutations
in the same pathways, providing the cell with selective
advantages that promote tumour progression. Strategies
to reverse epigenetic gene silencing might therefore be
useful in cancer prevention and therapy130. Moreover,
DNA demethylating agent 5-azacytidine has been cur-
rently used in human myelodisplastic disorders thera-
py131. Being aware that this agent has a detrimental ef-
fect upon mammalian embryonic development in vitro132
and in vivo133,134 one must be careful while using it on hu-
mans because of its teratogenic side effects.
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REGULACIJA EKSPRESIJE GENA U SISAVACA
S A @ E T A K
Nasljedne promjene u ekspresiji gena koje se naslje|uju neovisno o promjenama slijeda baza u molekuli DNA defi-
niraju pojam epigenetike. Zadnja dekada, pokazala je da epigenetski mehanizmi omogu}avaju dodatnu regulaciju eks-
presije gena na razini transkripcije. Tri sistema, uklju~uju}i metilaciju DNA, modifikaciju histona i RNA-posredovano
djelovanje, danas se povezuju s regulacijom ekspresije gena. Oni su kriti~ni regulatori kako embrionalnog razvoja tako i
samog rasta stanica. Proces metilacije molekule DNA predstavlja epigenetski mehanizam uklju~en u inaktivaciju
transkripcije gena, genomski imprinting, osigurava neaktivnost ve}ine gena na inaktivnom X kromosomu u stanicama
`enskog organizma kao i tumor supresor gena u raku. Ovim pregledom iznjeli smo osnovne principe metilacije DNA
molekule kao glavnog epigenetskog mehanizma regulacije genske ekspresije, s te`i{tem na njezinoj ulozi u normalnom
embrionalnom razvoju te poreme}ajima koji dovode do razvoja raka.
